<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT922-12756</title>
	</head>
	<body>
		<main>
			<p>920415 FT  15 APR 92 / International Company News: BioChem plans offering BIOCHEM Pharma, Glaxo's principal partner in Canada, is raising CDollars 115m (USDollars 96.6m) or more in new equity through a public offer in the US and Europe. The issue, which will total 3.5m shares with a further 525,000 available if demand is sufficient, is being underwritten by Morgan Stanley, Tucker Anthony and Kleinwort Benson. The offer will be made by late May. BioChem's stock trades in Canada and on NASDAQ in New York, and the company plans a London listing. It has been the leader in Canada's biotech industry for three years. Its new anti-Aids drug is being clinically tested and development is being funded by Glaxo. Glaxo plans to market the drug internationally when full approvals are received. AIR CANADA will reach break-even on operations within 12 months, Mr Hollis Harris, president, said.</p>
		</main>
</body></html>
            